Pfizer And Mylan Team Up For Generics Opportunity In Japan

TOKYO – Mylan NV is the third-largest generics firm in the world, but it has lagged behind domestic competition in Japan despite an extensive portfolio. Meanwhile, Pfizer Inc. has been eager to broaden its established brands unit. The solution? The U.S.-based companies have decided to share responsibilities to bring products to Japan’s growing generics market.